Provided herein are oral pharmaceutical compositions containing a GLP-1 analogue and/or insulin for treating and reducing the incidence of norialcoholic fatty liver disease (NAFLD), hepatic steatosis, and sequelae thereof, and methods of utilizing same.

Provided herein are oral pharmaceutical compositions containing a GLP-1 analogue and/or insulin for treating and reducing the incidence of norialcoholic fatty liver disease (NAFLD), hepatic steatosis, and sequelae thereof, and methods of utilizing same.

The present disclosure relates to processes for the production of peptides and methods of using peptides produced accordingly. Peptides produced according to the present disclosure may be administered for the treatment of autoimmune and/or inflammatory diseases and conditions.

The present disclosure relates to processes for the production of peptides and methods of using peptides produced accordingly. Peptides produced according to the present disclosure may be administered for the treatment of autoimmune and/or inflammatory diseases and conditions.

The use of the C-terminal region of one or more phytocystatin(s) for the curative or prophylactic treatment of tumors and/or inhibition of metastases in mammals or other vertebrates. In one embodiment, the pharmaceutical composition of the invention comprises a pharmaceutically acceptable carrier and a polypeptide containing only the C-terminal region of one or more phytocystatin(s). In another embodiment, the composition of the invention comprises a gene construct for the in vivo expression of said polypeptide.

The use of the C-terminal region of one or more phytocystatin(s) for the curative or prophylactic treatment of tumors and/or inhibition of metastases in mammals or other vertebrates. In one embodiment, the pharmaceutical composition of the invention comprises a pharmaceutically acceptable carrier and a polypeptide containing only the C-terminal region of one or more phytocystatin(s). In another embodiment, the composition of the invention comprises a gene construct for the in vivo expression of said polypeptide.

This invention provides compositions that include a protein and at least two protease inhibitors, method for treating diabetes mellitus, and methods for administering same, and methods for oral administration of a protein with an enzymatic activity, including orally administering same.

This invention provides compositions that include a protein and at least two protease inhibitors, method for treating diabetes mellitus, and methods for administering same, and methods for oral administration of a protein with an enzymatic activity, including orally administering same.

This invention provides compositions that include a protein and at least two protease inhibitors, method for treating diabetes mellitus, and methods for administering same, and methods for oral administration of a protein with an enzymatic activity, including orally administering same.

This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.